Orally taken or buccal antiviral medicament-Ribavirin tablet and method of preparing the same

Abstract

The invention discloses an antiviral drug which can be taken orally or molten - a ribavirin tablet and a manufacturing method thereof. The compositions of the preparation by weight percent are 3.8 to 20 percent of ribavirin, 71 to 83.25 percent of sugar and 9 to 12.95 percent of other pharmaceutic adjuvant. The manufacturing method comprises the following steps: 80 meshes of the ribavirin, 80 meshes of the sugar and other filler and disintegrating agent between 80 meshes and 100 meshes are taken and mixed; an adequate bonding agent is added into the mixture and particles are prepared, boiled, dried and integrated and added with lubricant; after uniform mixture, the weight of a stator plate is tested, and tabletting is performed; and after test qualification, packaging and full inspection are performed. The preparation lightens the passivity of patients in taking medicine and particularly solves the problem of medicine taking of infants, old patients, dental patients, upper respiratory tract virus infection patients and so on; and as shown by production for a plurality of years and sampling stability study, the quality of the preparation is stable.

Description

technical field [0001] The invention relates to an antiviral drug, in particular to a ribavirin tablet which can be taken orally or contained in an antiviral drug and a production method thereof. Background technique [0002] Ribavirin (English name: ribavirin), whose chemical name is 1-β-D-ribofuranosyl-1H-1.2.4-triazole-3-carboxamide, is a broad-spectrum antiviral drug. This product does not change virus adsorption, invasion and uncoating, nor does it induce the production of interferon. Inhibits the replication of most DNA and RNA. After the drug enters the cells infected by the virus, it is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthetase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing intracellular guanosine The reduction of triphosphate damages the synthesis of viral RNA and protein, and inhibits the replication and spread of the virus. Pharmaco...

AI Technical Summary

Problems solved by technology

In the published data report, as the title of the invention is "ribavirin oral solid dosage form and preparation method thereof", the patent document of patent No. CN98812485.8 discloses a production technology scheme, but the ribavirin used in this scheme Forest component is higher, and production cost is also high; In addition, the title of invention is " ribavirin sustained-release preparation ", and the patent No. is in the document of CN03100542.X, also discloses a kind of ribavirin sustained-release pellet and Its preparation method, the use of the dosage form of this technical scheme is limited, can not meet the market demand

Existing ribavirin tablets use medicinal starch and other auxiliary materials as fillers, have no sweet taste, and are mainly taken by swallowing. If the taste is very bitter in the mouth, patients cannot accept it.

Images